Dr. Alita Logrono Dizon, M.D. Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 377 Jersey Ave, Suite 460, Jersey City, NJ 07302 Phone: 201-332-4110 Fax: 201-332-4122 |
Paul S Weissman, MD Internal Medicine - Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 377 Jersey Ave Ste 460, Jersey City, NJ 07302 Phone: 201-332-4110 Fax: 201-332-4122 |
Paul M Stoopack, MD Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 600 Pavonia Ave, 3rd Floor, Jersey City, NJ 07306 Phone: 201-216-3065 Fax: 201-499-0250 |
Dr. Steven Joel Shiff, M.D. Internal Medicine - Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: Forest Research Institute, Harborside Financial Center, Plaza V, 21st Floor, Jersey City, NJ 07311 Phone: 201-427-8077 Fax: 201-427-8103 |
Arthur Chester Stowe Jr., MD Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 377 Jersey Ave Ste 460, Jersey City, NJ 07302 Phone: 201-332-4110 Fax: 201-332-4122 |
Mr. Ram K Reddy, M.D. Internal Medicine - Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 212 Palisade Ave, Jersey City, NJ 07306 Phone: 201-659-4095 |
News Archive
A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with scleroderma, according to results from an open-label Phase II trial. While the drug's efficacy must be demonstrated in a Phase III trial, the gold standard for testing a drug, researchers are optimistic that Gleevec- (imatinib) could potentially be a weapon against the chronic connective tissue disease for which a treatment has remained elusive.
When congenital cataract surgery is performed at an early age, central corneal thickness increases, show study results published in the British Journal of Ophthalmology.
Researchers at UPM and UWO have shown that performing supervised moderate-intensity exercise during pregnancy can prevent gestational hypertension in pregnant women and overweight in newborns.
Matrix-Bio, Inc., a diagnostics company that uses metabolite profiling to detect cancer and other diseases, has signed an exclusive global licensing and marketing agreement for metabolomic biomarkers with Quest Diagnostics, the world's leading provider of diagnostic information services. Under the agreement, Quest Diagnostics will have the rights to use the biomarkers for the future, potential development of a clinical lab-developed test to aid in the detection of breast cancer recurrence.
› Verified 7 days ago